Axinn Represents Purepac Pharmaceutical Company in Metformin Launch
January 1, 2004
Axinn represented Purepac Pharmaceutical Company in connection with its launch of various products containing the active ingredient metformin. The firm provided patent and FDA advice and also represented the company in two cases involving exclusivity disputes under the Hatch-Waxman Act. In one case, Axinn lawyers successfully obtained a temporary restraining order from the U.S. District Court for the District of Columbia against the Food & Drug Administration’s award of generic marketing exclusivity relating to metformin hydrochloride extended-release tablets, 500 mg, currently marketed by Bristol-Myers Squibb Company under the trade name Glucophage® XR. A hearing on Purepac’s motion for preliminary injunction was held on November 12, 2003, at which Axinn argued that FDA’s actions were arbitrary and capricious in light of the statutory mandates set forth in the Hatch-Waxman Amendments and FDA’s regulatory scheme. Purepac successfully negotiated a settlement of the case shortly thereafter.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating the Hart-Scott-Rodino Act in 2025
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
State by State, Pre-Merger Notifications Expand
Axinn Viewpoints
Antitrust
FTC claims diverging market from EU in Mars/Kellanova clearance
Media Mentions
Keeping an Eye on the Ball: America First Antitrust Weighs in on the “Uniquely American System of Scholar Athletics”
Axinn Viewpoints
Antitrust
Wait, We Have To Tell Who? What You Need To Know About State Premerger Notifications
Podcast
MBK | MSK Fellowship Summit 2025
Sponsorship
Antitrust